Eliminating Hepatitis C in Washington State

Improving lives and ending an epidemic through partnership

In case you missed it

HCA signed a contract with AbbVie, a research-based global biopharmaceutical company and maker of MAVYRET®, in an effort to eliminate HCV in Washington State by 2030. As part of this effort, AbbVie will coordinate with us to find individuals who are not yet treated; educate the health care workforce about screening and providing curative HCV treatment; and address barriers to care such as stigma, the lack of urgency among patients and providers to treat, and access to HCV specialists.

Additionally, the U.S. Food and Drug Administration (FDA) just announced in September 2019 that they have granted approval of AbbVie’s MAVYRET® to shorten the once-daily treatment duration from 12 to 8 weeks in treatment-naïve, compensated cirrhotic, chronic HCV patients across all genotypes. This approval provides more HCV patients an option to treat their disease in as little as 8 weeks and is supported by an overall 98 percent cure.

What we need from you

Action! This is a huge opportunity to rid our state of the most common blood borne disease in the United States – and now it is possible! Effective immediately, we would like all providers licensed to treat HCV to screen and treat the target population. In order to support our provider community in this monumental effort, HCA has made important policy changes:

- The antiviral MAVYRET® will no longer require prior authorization (PA), and is the preferred medication in the Antivirals: Hepatitis C Agents on the Apple Health Preferred Drug List. Other direct-acting antivirals will require review and will be approved only when MAVYRET® is not clinically appropriate.
- Anyone licensed to prescribe antiviral treatments is allowed to screen and treat Medicaid members to support this effort.

Important information

- AbbVie has a nurse ambassador program that we highly recommend. You can enroll your HCV patients, or encourage them to sign up themselves. [https://www.mavyret.com/patient-support](https://www.mavyret.com/patient-support)

- Please see HCA’s hepatitis C elimination webpage for more information and continued updates during this effort. [https://www.hca.wa.gov/about-hca/clinical-collaboration-and-initiatives/eliminating-hepatitis-c](https://www.hca.wa.gov/about-hca/clinical-collaboration-and-initiatives/eliminating-hepatitis-c)

- For questions email [eliminatehcv@hca.wa.gov](mailto:eliminatehcv@hca.wa.gov).